ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Year: 2018
Type: article
Source: Molecular Cancer Therapeutics
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Astex Pharmaceuticals
OpenAlex ID: W2802542587
